<?xml version="1.0" encoding="ASCII"?>
<biogps><data><item key="owner">ArrayExpress Uploader</item><item key="pop_total">0</item><item key="species">mouse</item><item key="factors"><item><item key="GSM1390726"><item key="TREATMENT">DMSO</item></item></item><item><item key="GSM1390726"><item key="TREATMENT">DMSO</item></item></item><item><item key="GSM1390726"><item key="TREATMENT">DMSO</item></item></item><item><item key="GSM1390726"><item key="TREATMENT">DMSO</item></item></item><item><item key="GSM1390726"><item key="TREATMENT">DMSO</item></item></item><item><item key="GSM1390726"><item key="TREATMENT">DMSO</item></item></item><item><item key="GSM1390732"><item key="TREATMENT">JQ1</item></item></item><item><item key="GSM1390732"><item key="TREATMENT">JQ1</item></item></item><item><item key="GSM1390732"><item key="TREATMENT">JQ1</item></item></item><item><item key="GSM1390735"><item key="TREATMENT">MLN8237</item></item></item><item><item key="GSM1390735"><item key="TREATMENT">MLN8237</item></item></item><item><item key="GSM1390735"><item key="TREATMENT">MLN8237</item></item></item></item><item key="id">7641</item><item key="ownerprofile_id">arrayexpress_sid</item><item key="platform">6</item><item key="summary_wrapped">Amplification of MYCN is the most prominent genetic marker of high-stage neuroblastoma, a childhood tumor originating from the neural...</item><item key="geo_gse_id">E-GEOD-57810</item><item key="owner_profile">/profile/8773/arrayexpressuploader</item><item key="factor_count">1</item><item key="sample_count">12</item><item key="tags"><item>cell</item><item>crest</item><item>line</item><item>neural crest</item><item>neuroblastoma</item></item><item key="lastmodified">Dec.12, 2014</item><item key="is_default">False</item><item key="geo_gds_id"/><item key="slug">expression-profiling-tumor-cells-from-mycn-driven</item><item key="geo_id_plat">E-GEOD-57810_A-AFFY-45</item><item key="name">Expression profiling tumor cells from MYCN-driven neuroblastoma upon BRD4 or AURKA inhibition</item><item key="created">Nov.12, 2014</item><item key="summary">Amplification of MYCN is the most prominent genetic marker of high-stage neuroblastoma, a childhood tumor originating from the neural crest. We generated a cell line (mNB-A1) from tumors developed in transgenic mouse and treated these cells with DMSO (n=6), the BRD4-inhibitor JQ1 (n=3) or the AURKA-inhibitor MLN8237 (n=3) for 24 h. The expression profiles of vehicle (DMSO)-treated mNB-A1 cells were compared to JQ1- or MLN8237-treated mNB-A1 cells.</item><item key="source">http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-57810</item><item key="sample_source">http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-57810/samples/</item></data></biogps>
